Nuzenio

From Crispr

From Crispr news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 9 latest news signals 6 publisher sources 100/100 entity strength

Latest news

Goldman Sachs Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP) - The Globe and MailThe Globe and Mail · Fri, 07 Aug 2026 12:02:00 GMTFrom CRISPR in Space to Public Radio: Bethlehem Ninth-Grader Aryash Shyam Named Host of WDIY’s Teen Scientist - The Valley LedgerThe Valley Ledger · Wed, 05 Aug 2026 02:11:27 GMTCiti Raises Price Target for CRISPR Therapeutics (CRSP) Amid Str - GuruFocusGuruFocus · Tue, 04 Aug 2026 18:22:30 GMTFrom CRISPR in Space to Public Radio: Indian American Ninth-Grader Aryash Shyam Named Host of WDIY's Teen Scientist - News India TimesNews India Times · Mon, 03 Aug 2026 19:39:29 GMTMorgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? - Yahoo FinanceYahoo Finance · Thu, 30 Jul 2026 07:00:00 GMTIntelliGenome Receives INVIMA Approval for CRISPR-TB Blood Test and Appoints Velez Lab as Exclusive | Newswise - NewswiseNewswise · Tue, 28 Jul 2026 23:15:00 GMTIntelliGenome Appoints Yu Shing Bio-Tech as Exclusive Distributor for CRISPR-TB in Taiwan | Newswise - NewswiseNewswise · Tue, 28 Jul 2026 23:10:00 GMTIntelliGenome Receives FDA Breakthrough Device Designation for CRISPR-TB Blood Test | Newswise - NewswiseNewswise · Tue, 28 Jul 2026 23:10:00 GMT

Timeline

Fri, 07 Aug 2026 12:02:00 GMTGoldman Sachs Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail
Wed, 05 Aug 2026 02:11:27 GMTFrom CRISPR in Space to Public Radio: Bethlehem Ninth-Grader Aryash Shyam Named Host of WDIY’s Teen Scientist - The Valley Ledger
Tue, 04 Aug 2026 18:22:30 GMTCiti Raises Price Target for CRISPR Therapeutics (CRSP) Amid Str - GuruFocus
Mon, 03 Aug 2026 19:39:29 GMTFrom CRISPR in Space to Public Radio: Indian American Ninth-Grader Aryash Shyam Named Host of WDIY's Teen Scientist - News India Times
Thu, 30 Jul 2026 07:00:00 GMTMorgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? - Yahoo Finance
Tue, 28 Jul 2026 23:15:00 GMTIntelliGenome Receives INVIMA Approval for CRISPR-TB Blood Test and Appoints Velez Lab as Exclusive | Newswise - Newswise

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for From Crispr.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

6 distinct publisher/source names are currently connected to this entity page.